Johnson & Johnson Partners with Sail Biomedicines to Advance CAR-T Cancer Therapy Pipeline

J&J has entered a strategic collaboration with biotech firm Sail Biomedicines to accelerate its chimeric antigen receptor T-cell development, aiming to outpace rival Bristol Myers Squibb in the immunotherapy space.